ArticleMedeniyet medical journal2025
Explaining Uncertain Hepatoprotective Effects: When Silibinin Co-Administered with Other Drugs.
Article in Medeniyet medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigated the herb-drug interaction between silibinin and carbamazepine (CBZ) and the potential risk of adverse drug reactions (ADR) when silibinin is co-administered with other drugs. Methods: Primary fresh hepatocytes were cultured, and an methylthiazolyldiphenyl-tetrazolium bromide assay was performed after administration of different concentrations of CBZ, and silibinin. Meanwhile, a retrospective study on hepatic adverse reactions involving the combination of silibinin with other drugs was performed using the Food and Drug Administration Adverse Event Reporting System (FAERS). Results: The protective effects of silibinin on CBZ do not appear on hepatocytes in a dose-dependent manner. When silibinin (25μM) was co-administered with CBZ (2mM), the cell viability increased from 47.8% to 75.9% (p<0.05), while increasing the silibinin concentration to 50μM with CBZ (2mM), the hepatocyte viability significantly declined from 47.8% to 38.7% (p<0.05). In the FAERS database, the risk of adverse reactions significantly increases when combined with silibinin. The silibinin co-administration was significantly associated with hepatotoxicity reports. Conclusions: The results of the cell experiment showed that silibinin's liver protective effects were uncertain when it was combined with CBZ. FAERS database analysis revealed elevated risks of ADRs with silibinin co-administration, collectively highlighting the necessity for vigilance against unanticipated herb-drug interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.